NasdaqCM:CELCBiotechs
Assessing Celcuity (CELC) Valuation After FDA Priority Review And Commercial Launch Preparations
Celcuity (CELC) has been in focus after the FDA accepted its New Drug Application for gedatolisib with priority review, while management simultaneously accelerates commercial preparation ahead of a potential launch.
See our latest analysis for Celcuity.
The share price has been volatile around these updates, with a 1 day share price return of negative 7.66% and a 30 day share price return of negative 5.09%. However, the 1 year total shareholder return is very large and indicates that longer...